Establishment Labs(ESTA) ZACKS·2025-05-07 22:10Core Insights - Establishment Labs Holdings Inc. reported a quarterly loss of $0.70 per share, which was better than the Zacks Consensus Estimate of a loss of $0.83, but worse than the loss of $0.58 per share from the previous year, indicating a 20.69% increase in loss year-over-year [1] - The company achieved an earnings surprise of 15.66% for the quarter, although it had a negative surprise of -58.06% in the previous quarter [1][2] - Revenue for the quarter was $41.38 million, slightly missing the Zacks Consensus Estimate by 0.06%, but showing a year-over-year increase from $37.17 million [2] Financial Performance - Over the last four quarters, Establishment Labs has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.55, with expected revenues of $51.88 million, while the estimate for the current fiscal year is -$2.05 on revenues of $208.6 million [7] Market Position - Establishment Labs shares have declined approximately 28.3% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's Zacks Rank is currently 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Context - The Medical Services industry, to which Establishment Labs belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, PACS Group, Inc., is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year increase of +10.5% [9]